Cargando…

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts

OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hogervorst, Milou A, Møllebæk, Mathias, Vreman, Rick A, Lu, Ting-An, Wang, Junfeng, De Bruin, Marie Louise, Leufkens, Hubert G M, Mantel-Teeuwisse, Aukje, Goettsch, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462958/ https://www.ncbi.nlm.nih.gov/pubmed/37640462 http://dx.doi.org/10.1136/bmjopen-2023-072309

Ejemplares similares

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Synergy between health technology assessments and clinical guidelines for multiple sclerosis
por: Hogervorst, Milou A., et al.
Publicado: (2023)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Missing data on accessibility of children’s medicines
por: Joosse, Iris R, et al.
Publicado: (2022)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study
por: Ogar, Comfort K., et al.
Publicado: (2023)

National medicines policies – a review of the evolution and development processes
por: Hoebert, Joëlle M, et al.
Publicado: (2013)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2013)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries
por: Leopold, Christine, et al.
Publicado: (2014)

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
por: Willemen, Marjolein J., et al.
Publicado: (2011)

Medicine shortages: impact behind numbers
por: Postma, Doerine J., et al.
Publicado: (2023)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia
por: Kibira, Denis, et al.
Publicado: (2021)

European guidelines for constitutional cytogenomic analysis
por: Silva, Marisa, et al.
Publicado: (2018)

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
por: Kibira, Denis, et al.
Publicado: (2021)

Chronic Q Fever Diagnosis—Consensus Guideline versus Expert Opinion
por: Kampschreur, Linda M., et al.
Publicado: (2015)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making of oncology medicines
por: Kalf, Rachel R. J., et al.
Publicado: (2021)

Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana
por: Tetteh, Raymond A., et al.
Publicado: (2015)

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
por: Tetteh, Raymond A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7p22g1qlr45h9qive71tdnlc5h